Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zenocutuzumab in NRG1 fusion-positive solid tumors
NL-OMON58733Phase 2Completed
- Sponsor
- Partner Therapeutics
- Start
- Feb 2015
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of zenocutuzumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma (PDAC) (9 arms), sponsored by Partner Therapeutics. Started Feb 2015; status: completed.
02
Drugs
zenocutuzumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON58733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58733.